Market Overview
The global biotechnology market size was valued at USD 1.85 trillion in 2025 and is expected to grow at a CAGR of 13.5% during 2026–2034. The drivers are developments in CRISPR-based gene therapy, AI drug discovery, heightened prevalence of chronic diseases, and government and R&D investments.
Biotechnology is emerging as a key driver of advancement in the healthcare and bio-industrial sectors. Biotechnology facilitates the development of advanced care through cell and gene therapy and the establishment of next-generation diagnostics. Biotechnology supports the development of sustainable biotech platforms for the agricultural and industrial sectors. This factor has paved the way for expanding the market and developing business models in the biotech industry.
Key Insights
- The DNA sequencing segment dominated the market in 2025 due to growing government expenditures on genetic studies and development in the area.
- The health segment is poised for strong expansion as the global disease burden continues to rise.
- The North America biotechnology market accounted for over 40% of the market share in 2025, driven by leading players, strong R&D, and heavy healthcare spending.
- The Asia Pacific biotechnology market is growing at a strong rate with higher investment, improved healthcare infrastructure, beneficial government policies, and strategic expansion by leading players.
Industry Dynamics
- Expansion of biotechnology innovation is being fueled by the development of personalized medicine and orphan drugs formulations, drawing new businesses and increasing revenue in the market.
- The rise in chronic diseases is being compounded by advancements in biotechnology and personalized medicine, prompting the industry to develop more specific and innovative remedies for genetic and chronic conditions.
- Rising demand for biotechnology devices in agriculture is propelling the market growth.
- High R&D expenses, strict and complicated regulatory requirements, and scalability challenges in the production stage can lead to delays in the commercialization of products.
- The major constraint on the biotechnology industry is the high cost and complexity of regulatory approvals for research and development. Commercialization challenges for new biotechnological products may also hinder market expansion.
Market Statistics
- 2025 Market Size: USD 1.85 trillion
- 2034 Projected Market Size: USD 5.80 trillion
- CAGR (2026-2034): 13.5%
- North America: Largest Market Share
AI Impact on Biotechnology Market
- Artificial intelligence (AI) enhances drug discovery by quickly searching across diverse datasets to identify the lead compounds.
- AI in biotechnology improves precision medicine by personalizing treatment programs based on an individual's genetic data.
- AI-driven predictive analytics help improve forecasts of disease outbreaks, and early interventions are also possible.
- AI is used in bioinformatics to analyze biological data to create new vaccines and treatments.
- Machine learning models make clinical trials more efficient by identifying suitable participants and predicting outcomes.
- In addition to automation, the applications of generative AI in biotech are expanding into the realms of target identification, protein design, antibody design optimization, and biomarker exploration, making it possible to reduce the early-stage failure rates.
- AI is also enabling clinical trial optimization through intelligent site identification, patient stratification, and real-time safety signal monitoring, especially for difficult-to-treat conditions or orphan diseases.
There have been important breakthroughs in gene therapies, especially those associated with CRISPR technology, which are opening avenues for curing genetic diseases. Moreover, AI technology is also driving faster drug discovery and development. So, the integration of AI in drug discovery is being increasingly done. The growth of chronic diseases has created the need for innovative biotechnology solutions.
Biotechnology is the application of biological systems, organisms, or their derivatives to develop products and technological solutions that help society. Biotech combines expertise from several domains, including biology, chemistry, and engineering. It provides solutions in healthcare, agriculture, and environmental sustainability.
Various government initiatives to modernize regulation and reimbursement are major market drivers. The growing use of personalized medicine and the availability of various orphan medicinal forms create biotechnology market opportunities. The entry of new, innovative players into the market also fuels this market's growth.
A robust clinical trial pipeline and available funding opportunities in tissue engineering and regeneration technologies propel the biotechnology market. According to the Alliance for Regenerative Medicine, companies involved in cell and gene therapies received over USD 23.1 billion in global investments in 2021, marking a 16% increase from the previous year's total of USD 19.9 billion. The clinical success of key gene therapy players in 2021, such as positive outcomes from Intellia Therapeutics and Regeneron's in vivo CRISPR treatment for transthyretin amyloidosis, has contributed to market growth.
The biotechnology value chain typically ranges from discovery research (targets, platforms, and datasets) to preclinical validation and clinical development. It also includes GMP manufacturing for biologics/cell therapy, as well as downstream commercialization at the market access, reimbursement, and distribution levels. Value often concentrates in defensible platforms, scalable manufacturing capability, and late-stage pipelines with clear regulatory and reimbursement pathways.
Driver Analysis
Increasing Prevalence of Chronic Illnesses
There has been a rise in the prevalence of chronic diseases. This has been due to an increasingly sedentary lifestyle, the expansion of the middle class, and rising urbanization. This shift contributes to higher rates of obesity. It also results in increased occurrence of diseases such as malaria, HIV, diabetes, TB, and genetic abnormalities. In addition, the market is driven by the growing incidence of target diseases and genetic disorders; advancements in polymerase chain reaction technology; and rising investments, funds, and grants that fuel scientific research. The bio-pharma sector has played a crucial role in preventing chronic diseases by focusing on personalized care. This trend seems to lay the groundwork for individual procedural healthcare requirements and could be beneficial in the care of hereditary genetic disorders. Additionally, innovative concepts such as cell therapy are entering the marketplace, exhibiting the potential for effective care for certain cancers.
Growing Demand in Agriculture
The market is growing due to increasing demand for biotechnology products in agricultural sectors such as micropropagation, molecular breeding, tissue culture, traditional plant breeding, and the development of genetically modified crops. The increasing popularity of herbicide-tolerant and insect-resistant seeds also fuels the growth of the market. The use of tissue culture technology for the growth and development of new rice strains and disease- and pest-free banana plant species in South Asia and Africa, and for the creation of disease-free and nutritious plant species, fuels the use of biotechnology in agriculture, thereby fueling the industry’s value.
Segment Analysis
Assessment by Technology Outlook
The biotechnology market segmentation based on technology includes fermentation, tissue engineering and regeneration, chromatography, PCR technology, nanobiotechnology, cell-based assays, DNA sequencing, and others. The DNA sequencing segment accounted for the largest share in 2024 due to an increase in government funding for genetic research. Government funding in genetic research has facilitated the expanded applications of sequencing, facilitating a better understanding of diseases. For instance, in May 2021, the University of Pittsburgh Graduate School of Public Health and Washington University School of Medicine received a USD 10.7 trillion NIH grant for the exploration of the genetic foundation of Alzheimer's disease, showcasing an increase in funding for genetic research, thereby driving the segmental growth in the global industry. In addition, the increased uptake of next-generation sequencing (NGS) has been driven by large-scale population genomics projects, the growing number of companion diagnostics procedures in the precision oncology market, and the continued decline in sequencing costs.
Nanobiotechnology is also likely to register significant growth, driven by rising approvals in nanomedicine and the introduction of new technologies. Being less toxic, smaller in size, and more versatile in their chemical properties, nanoparticles offer advantages for overcoming the challenges posed by traditional delivery methods for generic versions of medications. These attributes support the development of targeted drug delivery systems. And the rising regulatory approvals of nanomedicines are accelerating their transition from clinical research to commercial therapeutics. In addition, the field of tissue engineering and regenerative medicine accounts for a noteworthy share. This is supported by government and private investments, as well as substantial healthcare expenditure. The presence of several established and new players also contributes to the growth.
Assessment by Application Outlook
The biotechnology market segmentation, based on application, includes bioinformatics, food and agriculture, health, industrial processing, natural resources and environment, and others. The health segment of the market is expected to experience significant growth due to the increasing burden of diseases worldwide. The global population is aging. And the prevalence of chronic conditions like cancer, diabetes, and heart disease is rising. As a result, there has been greater demand for sophisticated treatments and therapies. This is where biotechnology comes into play, with its main focus on developing new medicines, vaccines, and diagnostic solutions. Additionally, the growth of personalized medicine and gene therapy is driving the segment.
Regional Analysis
In 2025, the North America biotechnology market accounted for more than 40% of the global market share. The growth of the regional market is driven by various factors. They include the presence of key players, extensive research and development activities, and substantial healthcare expenditure. The region exhibits a notable penetration of genomics, proteomics, and cell biology-based platforms, thereby accelerating the adoption of life sciences tools. This is further reinforced by a dense network of academic medical centers, mature venture capital funding, a strong intellectual property ecosystem, and well-set-up regulatory pathways to enable the faster translation of research into commercial products. Additionally, the increasing prevalence of chronic diseases and the growing adoption of personalized medicine applications for treating life-threatening disorders are anticipated to have a positive impact on biotechnology market growth in the North American region.
The Asia Pacific biotechnology market is experiencing significant growth. This growth is due to increasing investments, enhancements in healthcare infrastructure, favorable government initiatives, and strategic expansion efforts by key market players. Notably, in February 2022, Moderna Inc. disclosed plans for a geographic expansion of its commercial network in Asia. It established new subsidiaries in Malaysia, Singapore, Hong Kong, and Taiwan. Furthermore, collaborations in the biopharmaceutical sector, such as the strategic partnership between Kiniksa Pharmaceuticals and Huadong Medicine for the development and commercialization of Kiniksa's ARCALYST and mavrilimumab in the Asia-Pacific region, showcase the strategic expansion efforts by key market players. At the same time, the region is focusing on the creation of a stronger biotechnology ecosystem. It is doing so through the expansion of biomanufacturing facilities and increasing the number of clinical trials. Together, these efforts help biotech companies accelerate scale up.
Key Players & Competitive Analysis Report
The biotechnology industry is constantly evolving. There are many firms putting effort into innovating and emerging as distinct. The major international firms are controlling this industry through extensive research and development and advanced methods. The biotechnology market companies are pursuing strategies such as mergers and acquisitions, collaborations, and partnerships to enhance their product lines and expand into emerging markets.
New companies are impacting the industry by introducing innovative products to meet the demand of specific market sectors. This competitive landscape is amplified by continuous progress in product offerings. Major players in the biotechnology market include Abbott Laboratories, Amgen Inc., AstraZeneca, Biogen, Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., Johnson & Johnson Services, Inc., Lonza, Merck KGaA, Novartis AG, Novo Nordisk A/S, Pfizer, Inc., and Sanofi.
F. Hoffmann-La Roche Ltd
Roche has been known for excellent integration between biologics and diagnostics, giving it a competitive edge in personalized healthcare. Roche has a deep commitment to oncology, driven by its complementary strengths in immunology, neuroscience, ophthalmology, and infectious diseases. An important strategic thrust area that Roche has maintained over the years has been to combine targeted medicines with companion diagnostics to enhance outcomes. In recent years, Roche has maintained its pipeline strength through its chosen partnerships and acquisitions. The focus of these strategic developments is to sustain its growth in specialties and personalized healthcare in the coming years.
Novartis AG
Novartis is a global innovator with strong R&D capabilities in small molecules and biologics, and a diverse clinical and manufacturing footprint. Its main therapeutic areas of interest lie in oncology, cardio-renal, immunology, neuroscience, hematology, and ophthalmology. In addition to restructuring its portfolio into higher-value offerings, Novartis has leveraged other partnerships. They include its alliance with Alnylam Pharmaceuticals to advance RNAi therapeutics. Simultaneously, Novartis is investing heavily in next-gen manufacturing and targeted acquisitions to further establish itself at the forefront of the speciality drugs segment.
Key Companies
- Abbott Laboratories
- Amgen Inc.
- AstraZeneca
- Biogen
- Bristol-Myers Squibb
- F. Hoffmann-La Roche Ltd.
- Gilead Sciences, Inc.
- Johnson & Johnson Services, Inc.
- Lonza
- Merck KGaA
- Novartis AG
- Novo Nordisk A/S
- Pfizer, Inc
- Sanofi
Industry Developments
In May 2025, Nestlé unveiled a strategic restructuring of its global R&D operations, strengthening its biotechnology capabilities and launching a new deep tech center in Orbe, Vaud canton. The initiative is designed to accelerate innovation while improving overall operational efficiency.
In October 2024, the Unified Website for Biotechnology Regulation was launched by the USDA, EPA, and FDA. This website contains information regarding regulatory requirements for GM microorganisms. This move is aimed at improving transparency and coordination in biotech regulation.
In May 2023, Gilead Sciences, Inc. announced the completion of its acquisition of XinThera, obtaining all outstanding shares. This strategic maneuver advanced Gilead's clinical development goals by combining complementary pipeline assets targeting validated oncology and inflammation targets.
In January 2023, Gero and Pfizer initiated a strategic research collaboration. According to Gero, the partnership will leverage Pfizer's domain expertise and Gero's advanced technology platform. It is focused on uncovering genes and pathways linked to fibrotic diseases.
Research Methodology
The biotechnology market size analysis and forecasts for growth rate are obtained by combining secondary research methodology with primary research. The secondary research methodology involves company documents, press releases, and industry databases. Primary inputs include expert research network interviews pertaining to the biotechnology industry value chain. These findings are then validated through triangulation approaches, which involve bottom-up and top-down analysis.
Biotechnology Market Segmentation
By Technology Outlook (Revenue – USD Trillion, 2021–2034)
- Fermentation
- Tissue Engineering and Regeneration
- Chromatography
- PCR Technology
- Nanobiotechnology
- Cell-based Assays
- DNA Sequencing
- Others
By Application Outlook (Revenue – USD Trillion, 2021–2034)
- Bioinformatics
- Food & Agriculture
- Health
- Industrial Processing
- Natural Resources & Environment
- Others
By Regional Outlook (Revenue – USD Trillion, 2021–2034)
- North America
- US
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Netherlands
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Malaysia
- South Korea
- Indnesia
- Australia
- Vietnam
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Mexico
- Brazil
- Argentina
- Rest of Latin America
Biotechnology Market Report Scope
|
Report Attributes |
Details |
|
Market Size in 2025 |
USD 1.85 trillion |
|
Market Size in 2026 |
USD 2.10 trillion |
|
Revenue Forecast by 2034 |
USD 5.80 trillion |
|
CAGR |
13.5% |
|
Base Year |
2025 |
|
Historical Data |
2022–2024 |
|
Forecast Period |
2026–2034 |
|
Quantitative Units |
Revenue in USD trillion, 2021–2034 and CAGR from 2026 to 2034 |
|
Report Coverage |
Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
|
Segments Covered |
|
|
Regional Scope |
|
|
Competitive Landscape |
Biotechnology Industry Trend Analysis (2025) Company profiles/industry participants profiling include company overview, financial information, product/service benchmarking, and recent developments |
|
Report Format |
PDF + Excel |
|
Customization |
Report customization as per your requirements with respect to countries, regions, and segmentation. |
FAQ's
The biotechnology market stood at USD 1.85 trillion in 2025.
The global market is projected to grow at a CAGR of 13.5% during the forecast period, 2026-2034.
The development of personalized medicine and the rise in chronic conditions are a few of the factors driving growth.
DNA sequencing and nanobiotechnology are the fastest-growing biotechnology technologies.
North America leads the market for biotechnology due to its extensive R&D activities and the presence of several key players.
The health segment is market is expected to experience significant growth in the biotechnology market due to the increasing burden of diseases worldwide.
Page last updated on:
Mar-2023
Research Methodology
A robust system of research, verification, and forecasting designed to ensure reliable and actionable market insights.
Polaris Market Research uses a clear and structured approach to deliver insights that clients can rely on. The process combines detailed primary and secondary research, including direct communication with industry experts. The detailed information helps build a complete picture of market trends and developments. Secondary data is gathered from credible sources such as industry reports, company filings, government source links, and trusted organization databases. It is then cross-checked through discussions with key stakeholders across the value chain. Market size and forecasts are developed using both bottom-up and top-down methods to ensure accuracy and consistency in the final results.
Project Setup
Step 1 & 2:
- We start every project by clearly understanding the client’s objective or goal, then defining the market scope, and aligning regions, segments, and timelines.
- Once the foundation is set, we collect data from all-around of sources, including company reports, government databases, and paid industry platforms.
- Our research is based on secondary data, which helps us build a strong understanding of the market across regions and industries. Then we validate this information through primary research by speaking directly with industry experts, companies, and stakeholders.
- By combining secondary and primary research, we ensure that our market insights are accurate, practical, and closely aligned with real market conditions.
Data Collection
We gather information from both public and verified sources:
Data Structuring
Step 3:
- All collected data is organized into a consistent format to ensure accurate analysis. Since inputs come from multiple sources, they are standardized and aligned before use.
- The data is segmented by product, application, and region, and mapped across a defined historical period (2020–2024). All values are converted into common units (USD Mn/Bn), and volume and pricing are aligned where required to estimate revenue.
- Any overlaps or inconsistencies are reviewed and adjusted to maintain accuracy (<5% variance threshold).
- The result is a structured dataset that allows for clear comparison across regions and supports reliable analysis and forecasting.
Structured Market Dataset, USD Mn/Bn
4. Data Structuring
Step 4: TOP-DOWN APPROACH
- We start with the overall market size at a global or macro level.
- The market is then narrowed down based on scope and industry relevance.
- We apply penetration rates and split the data by region and segment.
- This helps us estimate the market size for specific segments.
- The numbers are validated through cross-checks to ensure accuracy.
Step 5: BOTTOM-UP APPROACH
- We begin by analyzing data from leading companies in the market.
- Revenue data is collected and mapped across different segments.
- The data is then aggregated to estimate the total market size.
- To fill in any gaps, adjustments are made based on industry standards.
- Validation checks make sure that the results are correct.
5. Data Structuring
Step 6:
At Polaris Market Research, we employ a methodical forecasting strategy. This approach blends the analysis of historical data with real-time market validation. To forecast future trends with precision, we examine past patterns, pricing fluctuations, and the interplay of supply and demand. To ensure our conclusions reflect the present market landscape, we actively seek input from industry experts and key stakeholders.
To refine our predictions, we carefully consider critical elements such as market drivers and restraints, fluctuations in raw material costs, emerging technologies, and the production capabilities of various regions. Furthermore, we assess regulatory frameworks and potential policy shifts to gauge their potential impact on market expansion.
All this information is synthesized to generate precise forecasts for each segment and region. These forecasts illuminate the current state of the market and highlight forthcoming opportunities.
6. Data Structuring
Step 7:
In the final stage, we validate all our estimates using a triangulation method, where data is cross-checked from multiple reliable sources, like company data, primary interviews, and secondary research. This helps us make sure that our numbers are correct and fit with the rest of the market.
This process involves verifying data consistency across various segments and geographic areas. It also requires comparing historical trends with the assumptions support the forecast. Any discrepancies involve adjustments to ensure everything remains aligned and dependable.
Once the data is finalized, we prepare the final outputs, including market size estimates, segment-wise breakdowns, and growth metrics. These are delivered in structured formats such as tables, charts, and data files for easy analysis and use.
We collaborate closely with clients, ensuring the final products align with their requirements. This includes offering tailored adjustments, supplementary data analyses, and continuous assistance. Furthermore, we monitor market trends post-delivery, providing updates and refinements to maintain the insights' relevance as time passes.
Post-delivery, we continue to monitor market shifts, offering updates and adjustments to ensure the insights remain relevant over time.
Validation
Triangulation Framework
- Company-level data
- Primary inputs from industry participants
- Secondary benchmarks and published data
- Variance maintained within ±5-10%
- Adjustments applied to align estimates
- Segment values validated against overall market structure
Quality Check
Data Consistency & Integrity
- Segment totals validated to 100%
- Regional estimates aligned with global market size
- Historical trends compared against forecast outputs
- Assumptions reviewed for cross-segment and regional alignment
Output & Delivery
Final Outputs
- Market size estimates (USD Mn/Bn)
- Segment-wise distribution (%)
- Growth metrics (CAGR %)
- Structured tables and charts
- Segment-level datasets
- Excel-based data files for further analysis
Client Alignment & Support
- Deliverables are aligned with defined client requirements and scope
- Custom data cuts and segment splits are incorporated as required
- Post-delivery queries are addressed through analyst interactions
- Additional clarifications and data support are provided upon request
Client Continuity & Updates
- Market developments are tracked post-delivery to capture changes in key trends
- Updated data and revisions are provided based on new market inputs
- Additional refinements and data cuts are shared as required
- Continued analyst engagement supports evolving client requirements
